Abstract:p300/CBP bromodomain plays an important role in transcriptional regulation, and its overexpression is closely related to various diseases such as cancers. Two inhibitors of this target are currently in clinical trials but only CCS1477 (A1) have been published with the chemical structure. Herein, we modified the structure of CCS1477 based on the principle of bioisosterism and reasonable scaffold hopping, and discovered a series of new p300 bromodomain inhibitors with improved potency. More tumor cell lines sensitive to p300/CBP bromodomain inhibition were also identified. Among our new inhibitors, (R)-5-methylpyrrolidin-2-one derivitive B4 was the most potent one which showed comparable inhibitory activity against p300 (IC50 = 0.060 mu M) as lead A1 (IC50 = 0.064 mu M) at molecular level, and performed more potent proliferation inhibitory activities on various tumor cells than A1. Further we found that compound B4 had the high cell permeability and overcame the defect of the high efflux rate of A1, which could also explain the possible reason why B4 showed more potent inhibitory activities on sensitive tumor cells than lead A1. Western blotting analysis proved the target effects that B4 could suppress the expression of c-Myc and reduce H3K27 acetylation significantly. Liver microsomal metabolic stability assay and hERG channel inhibition evaluation illustrate compound B4 is metabolic stabilizable in human liver microsomes and has no hERG risk, which further demonstrate the good drug-likeness of B4. Therefore, compound B4 is a promising compound for further optimization and development.

Total Synthesis and Evaluation of B‐Homo Palmatine and Berberine Derivatives As P300 Histone Acetyltransferase Inhibitors

Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors

Synthesis and Cytotoxicity Evaluation of 13-N-alkyl Berberine and Palmatine Analogues As Anticancer Agents.

Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Discovery of Highly Potent, Selective, and Orally Efficacious P300/cbp Histone Acetyltransferases Inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy

Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors

Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine

Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Development of Novel 9-O-substituted-13-octylberberine Derivatives As Potential Anti-Hepatocellular Carcinoma Agents

Design and Synthesis of C3‐Substituted Β‐carboline‐based Histone Deacetylase Inhibitors with Potent Antitumor Activities

Development of Novel Β-Carboline-based Hydroxamate Derivatives As HDAC Inhibitors with Antiproliferative and Antimetastatic Activities in Human Cancer Cells.

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

Synthesis and Biological Evaluation of Thiophene-Based Hydroxamate Derivatives As HDACis with Antitumor Activities

Design, Synthesis and Biological Evaluation of Novel Nitric Oxide-Donating Protoberberine Derivatives As Antitumor Agents.